Luminex Corporation (LMNX) : Wall Street Access Asset Management scooped up 100 additional shares in Luminex Corporation during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Nov 14, 2016. The investment management firm now holds a total of 244,619 shares of Luminex Corporation which is valued at $5,195,708.Luminex Corporation makes up approximately 2.99% of Wall Street Access Asset Management’s portfolio.
Other Hedge Funds, Including , Balyasny Asset Management sold out all of its stake in LMNX during the most recent quarter. The investment firm sold 21,759 shares of LMNX which is valued $462,161.Carleon Capital Partners boosted its stake in LMNX in the latest quarter, The investment management firm added 1,120 additional shares and now holds a total of 27,973 shares of Luminex Corporation which is valued at $589,951. Luminex Corporation makes up approx 0.25% of Carleon Capital Partners’s portfolio.Swiss National Bank reduced its stake in LMNX by selling 2,100 shares or 3.2% in the most recent quarter. The Hedge Fund company now holds 63,500 shares of LMNX which is valued at $1,247,775.
Luminex Corporation opened for trading at $20.95 and hit $21.22 on the upside on Monday, eventually ending the session at $21.04, with a gain of 0.43% or 0.09 points. The heightened volatility saw the trading volume jump to 1,67,063 shares. Company has a market cap of $917 M.
On the company’s financial health, Luminex Corporation reported $0.21 EPS for the quarter, beating the analyst consensus estimate by $ 0.03 according to the earnings call on Oct 31, 2016. Analyst had a consensus of $0.18. The company had revenue of $71.20 million for the quarter, compared to analysts expectations of $68.60 million. The company’s revenue was up 17.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.22 EPS.
Many Wall Street Analysts have commented on Luminex Corporation. Avondale Initiated Luminex Corporation on Oct 12, 2016 to “Mkt Outperform”, Price Target of the shares are set at $27.Luminex Corporation was Upgraded by JP Morgan to ” Neutral” on Aug 18, 2016.
Luminex Corporation is a developer manufacturer and marketer of biological testing technologies with applications throughout the clinical diagnostic and life science industries. The Companys xMAP (Multi-Analyte Profiling) technology is being used within fields of drug discovery and development and for clinical diagnostics genetic analysis bio-defense food safety and biomedical research. In addition to its xMAP technology the Company has its MultiCode technology used for real-time polymerase chain reaction (PCR) and multiplexed PCR assays. The instruments in the Companys xMAP line include LX200 system which offers 100-plex testing; FLEXMAP 3D system which is a 500-plex testing system; and MAGPIX system which provides 50-plex testing at a lower cost using imaging rather than flow cytometry. The Companys products include Instruments Consumables Software and Assay Product Families.